Press coverage about Avinger (NASDAQ:AVGR) has been trending somewhat positive this week, according to Accern. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Avinger earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned news articles about the medical device company an impact score of 45.1800135509743 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Separately, Zacks Investment Research downgraded shares of Avinger from a “buy” rating to a “hold” rating in a research report on Monday, July 17th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Avinger presently has an average rating of “Hold” and a consensus price target of $5.00.
Avinger (NASDAQ:AVGR) traded up 3.4855% on Thursday, reaching $0.3355. 1,306,166 shares of the company’s stock traded hands. The stock has a 50 day moving average price of $0.31 and a 200 day moving average price of $0.31. Avinger has a 12-month low of $0.21 and a 12-month high of $4.89. The stock’s market cap is $8.02 million.
Avinger, Inc is a commercial-stage medical device company. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease (PAD). The Company focuses on introducing products based on its lumivascular platform, which is an intravascular image-guided system.